Company Overview
CORONA Remedies Limited (BSE: 544644, NSE: CORONA) reported strong financial performance for FY 2025-26 with consolidated revenue growth of 17.28% to ₹1,403.18 Crores and PAT growth of 33.45% to ₹199.42 Crores (excluding one-time statutory impact of ₹19.10 Crores from new Labour Codes). The company significantly outperformed the Indian Pharmaceutical Market growth of 8.59% by 859 basis points, improving its market rank to #27 from #32 in 2023.
Financial Performance & Operational Highlights
Key financial metrics showed robust improvement: EBITDA margin expanded to 20.9% (vs 20.1% in FY25), PAT margin reached 14.2% (vs 12.5%), ROCE stood at 40.79%, and ROE at 29.16%. The chronic portfolio contributed 71.94% of revenue, with 13 new product launches in the Defined Covered Market. The company maintained efficient working capital management with net working capital days of 27 days.
Strategic Developments & IPO
Corona Remedies successfully completed its IPO in December 2025 with 101.01x oversubscription (QIB: 117.52x, NII: 219.49x) through an offer for sale of 61,74,051 equity shares at ₹1,062 per share. The company expanded strategically through acquisitions of 8 brands, including 7 from Bayer Zydus Pharma and Wokadine® from Dr. Reddy's Laboratories for ₹96.90 Crores. Manufacturing capacity increased with addition of 400 million tablet capacity at the Gujarat facility, which received EAU GMP accreditation enabling entry into Eurasian markets.
ESG & Sustainability Performance
The company demonstrated strong ESG credentials with zero incidents of child labor, forced labor, sexual harassment, or workplace discrimination. Environmental investments included 5.55 MW solar capacity (1.3 MW plant + 4.25 MW solar park investment), LED lighting conversion, and tree plantation initiatives. GHG emissions totaled 36,575.77 tCO2e (Scope 1: 29,303.26, Scope 2: 7,272.51), with comprehensive waste management systems handling 113.79 MT of total waste.
Corporate Governance & AGM Details
The 22nd Annual General Meeting is scheduled for July 9, 2026, with agenda items including declaration of final dividend of ₹10 per equity share (100% of face value), re-appointment of directors, appointment of Walker Chandiok & Co LLP as statutory auditors for 5 years, and remuneration approvals. The board composition includes Dr. Kirtikumar Mehta as Non-Executive Chairman, Mr. Nirav Mehta as MD & CEO, and Mr. Ankur Mehta as Joint MD, with well-structured committees overseeing audit, nomination, risk management, and CSR.
Risk Management & Financial Position
The company maintains prudent risk management with foreign currency exposure limited to USD 0.26 Crore receivables and EUR 0.01 Crore payables. Liquidity is managed through cash flows from operations and short-term credit facilities. The capital structure shows net cash position of (₹14.70) Crores with debt-equity ratio of 0.19 times. CSR expenditure increased to ₹2.86 Crores (1.53% of average net profits) focused on healthcare, education, animal welfare, and armed forces veterans.
Regulatory Compliance & Future Outlook
The company maintains full compliance with SEBI Listing Regulations, Companies Act 2013, and environmental laws. With strong financial performance, successful IPO completion, strategic acquisitions, and robust ESG framework, Corona Remedies is well-positioned for continued growth in the pharmaceutical sector while maintaining high standards of corporate governance and regulatory compliance.